CClinicalTrials.gg
CompletedNCT02524470VSPUpdated May 31, 2017

Vital Signs Patch Early Feasibility and Usability Study v1.0

An interventional study of VSP System - NEHB Configuration and VSP System - PAL Configuration in Vital Signs, sponsored by LifeWatch Services, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-31.

Sponsored by LifeWatch Services, Inc. · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was Jul 2015, 11 years 2 months ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

To assess the feasibility and usability of the Vital Signs Patch (VSP) System in the in-patient hospital setting to monitor vital signs using a patch, brain, gateway, and console. The VSP System will be incorporated into the study site's Information Technology infrastructure.

Read the detailed description

The primary objective of this clinical feasibility study is to evaluate the feasibility of the Vital Signs Patch System (VSP). The VSP will be incorporated into the study site's Information Technology infrastructure and worn by in-patients for a minimum of 3 days and for the duration of their hospital stay up to 7 days.

The VSP will take and monitor vital signs in addition to the normal equipment the facility uses to monitor and take vital signs. This study will not be assessing safety and no comparator groups will be used. As this study will not be treating any particular disease or condition, no randomization or blinding is required. Subjects will be chosen as they are admitted in accordance with the general population characteristics, inclusion and exclusion criteria and willingness to sign the Informed Consent.

This clinical study involves a device with no additional drugs administered.

During this study, a single VSP System patch will be worn for up to 48 hours. The first patch will be placed using the NEHB configuration. After the first 48 hours, the NEHB-configured patch will be replaced with a new patch in the PAL configuration. The second patch can remain on the subject for the duration of the subject's hospital stay, or up to seven (7) consecutive days. Individual patient use will determine the duration of time that the second patch can be worn.

02

Conditions studied

  • Vital Signs
03

In context

Lead sponsor

LifeWatch Services, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Adult male and female in-patients with vital signs considered 'stable' by clinical caregivers.

Exclusion criteria

Exclusion Criteria:

  • Pediatric patients
  • Female patients who are pregnant
  • Patients with internal or external defibrillators
  • Patients who have undergone surgery and still have a fresh incision on the chest.
  • Patients with skin damage on the chest such as burns, irritation, infections, wounds, etc.
  • Patients in the Critical Care Unit (CCU)
  • Patients who otherwise satisfy any of the contraindications associated with the VSP system.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    VSP Study Participants

    Vital Signs Patch system study participants. Each study participant will receive the VSP System - NEHB Configuration and then the VSP System - PAL Configuration. Vital signs will be taken and adhesive will be assessed for each participant for each configuration.

    Device: VSP System - NEHB Configuration · Device: VSP System - PAL Configuration

Interventions

  • DeviceVSP System - NEHB Configuration

    VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.

  • DeviceVSP System - PAL Configuration

    VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.

06

What researchers measure

Primary outcomes

  1. Composite Outcome Measure - 100% Successful Vital Signs Acquisition

    Successful acquisition of Temperature, Heart Rate, ECG, Respiration, and SpO2 daily for the inpatient stay of the subject up to seven days. Success is achieved if all vital signs are obtained on a study participant. It is a composite result.

    Time frame: Up to seven days

Secondary outcomes

  1. Composite Outcome Measure - Adhesive Performance - Measurement of skin irritation resulting from adhesive used with electrodes.

    Successful performance of the adhesive of the patch throughout the study for each subject. Subject skin will be checked daily to determine if irritation has resulted where the electrodes have been placed. The results will be either positive or negative for skin irritation. This is a composite outcome measure.

    Time frame: Up to seven days

07

Study locations

1 site
  • University of Miami, Miller School of Medicine
    Miami, Florida 33136, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02524470
Lead sponsor
LifeWatch Services, Inc.
Responsible party
Sponsor
First posted
Aug 14, 2015
Start date
Jul 2014
Primary completion
Jul 17, 2015
Completion
Jul 17, 2015
Last update
May 31, 2017

Study contacts

Raul Mitrani, MD FACC FHRS
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion